FDA Rejects Atara's Cancer Treatment Application
Atara Biotherapeutics (ATRA) receives second FDA rejection for EBVALLO cancer therapy despite resolving manufacturing issues, citing concerns about clinical trial design.
/ 907 items
#Healthcare↓
Lyra Therapeutics Halts Drug Development, Cuts Entire Workforce
Lyra Therapeutics suspends LYR-210 development for chronic rhinosinusitis, lays off 28 employees, and explores strategic alternatives as stock plummets 44% in premarket trading.
Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.
REGENXBIO Shares Jump on Promising Duchenne Gene Therapy Results
REGENXBIO stock rises 8% after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
FDA Requests Additional Data on Stoke's Dravet Syndrome Treatment
Stoke Therapeutics continues discussions with FDA for expedited approval of zorevunersen for Dravet syndrome after regulators request more information on the epilepsy treatment.